PolyPeptide Group AG (SIX: PPGN) is a specialized global CDMO and market leader in peptide-based active pharmaceutical ingredient manufacturing. Supports pharmaceutical and biotech companies from pre-clinical through commercial scale. Operates six production sites worldwide with over 70 years of experience and 1,000+ GMP peptides manufactured. Strong exposure to GLP-1 therapies for metabolic diseases (diabetes, obesity). Currently expanding with a EUR 100M investment to double solid-phase peptide synthesis capacity at Malmo, Sweden. Also expanding in Belgium and Ambernath, India. Recently added oligonucleotide capabilities. Publicly traded on SIX Swiss Exchange.
Peptide API GMP manufacturing (solid-phase and liquid-phase), GLP-1 peptide production, oligonucleotide APIs, peptide process development, pre-GMP development, green peptide chemistry
5 sites worldwide
No reviews available yet.
No documents available.